Protara Therapeutics, Inc. (TARA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TARA Stock Price Chart Interactive Chart >
TARA Price/Volume Stats
| Current price | $3.49 | 52-week high | $11.10 |
| Prev. close | $3.31 | 52-week low | $2.72 |
| Day low | $3.40 | Volume | 11,100 |
| Day high | $3.60 | Avg. volume | 36,985 |
| 50-day MA | $4.15 | Dividend yield | N/A |
| 200-day MA | $5.86 | Market Cap | 39.27M |
Protara Therapeutics, Inc. (TARA) Company Bio
Protara Therapeutics, Inc. operates as a biotech company. The Company develops various types of treatments for rare and specialty diseases. Protara Therapeutics serves customers in the State of New York.
Latest TARA News From Around the Web
Below are the latest news stories about Protara Therapeutics Inc that investors may wish to consider to help them evaluate TARA as an investment opportunity.
Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology ConferenceNEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on February 9, 2022 at 4:00 PM ET. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https:/ |
Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical OfficerNEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, an |
Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual ConferenceNEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright BioConnect Virtual Conference being held from January 10-13, 2022. The prerecorded presentation will become available on Monday, January 10, 2022 at 7:00am ET and can be accessed by visiting the Events and Pr |
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview– TARA-002 Confirmatory Large-Scale GMP Comparability Complete – – U.S. FDA Cleared the Company’s IND Application for TARA-002 in NMIBC; Company Plans to Initiate Phase 1 Clinical Trial by Year-End – – Strong Cash, Cash Equivalents, and Marketable Debt Securities of $138.4M as of September 30, 2021 – NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, tod |
TARA Price Returns
| 1-mo | -7.43% |
| 3-mo | -24.30% |
| 6-mo | -50.14% |
| 1-year | -63.19% |
| 3-year | -79.23% |
| 5-year | -93.02% |
| YTD | -48.30% |
| 2021 | -72.12% |
| 2020 | 47.62% |
| 2019 | -81.94% |
| 2018 | 19.47% |
| 2017 | 0.00% |
Loading social stream, please wait...